The future felt uncertain when Dan and I were each diagnosed with Multiple Sclerosis back in 2000 and 1997, respectively. There were treatments available, but the options were limited. Many of the conversations centered around managing symptoms and slowing disease progression. After nearly three decades…
First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses, reduced signs of MRI disease activity, and better disability outcomes compared with those given the older drug Aubagio (teriflunomide) as their…
There are versions of myself hidden everywhere: in the back of closets, in drawers, in storage bins I’ve never unpacked because some part of me was unwilling to let go. I’ve kept old clothes that no longer feel like me (and certainly don’t feel good on), photos I should … Continue reading → Source:…
Tweet The CONSONANCE trial was a trial of ocrelizumab De Meo E, Jolly AE, Ganzetti M, Prados Carrasco F, Kanber B, Stutters J, McManus D, Kazlauskaite A, Craveiro L, Eshaghi A, Cole J, Chard D, Barkhof F. Disability profiles in progressive multiple sclerosis reflect pathology…
Tweet ChariotMS is coming of age. We started recruiting in July 2021, completed that in Jan 2025 and data lock for the 204 (of 200 planned) participants is in April 2027, so in less than one year. We are therefore planning ahead, thinking what success…
Tweet Getting ocrelizumab first line offers benefits over getting ocrelizumab second line, meaning you have failed treatment. In these scenarios they are both as effective at controlling relapse rate but when you get it first line you progress slower, telling us that progression is in…
The Multiple Sclerosis Association of America (MSAA) is expanding its patient-centered research network to include more than 1,000 people with multiple sclerosis (MS) receiving care at 20 sites across the U.S. Known as the Multiple Sclerosis Implementation Network (MSIN), the initiative brings together healthcare providers, researchers, people…
Living with MS brings many unexpected changes. While much focus is placed on physical symptoms, one of the biggest impacts of MS can be on our social circles. Relationships, marriages, and friendships might undergo a massive shift after a diagnosis, … Continue reading → Source:…
Living with multiple sclerosis (MS) can sometimes mean dealing with relapses, when new or worsening symptoms appear. To help shorten these flare-ups and make them less intense, doctors often prescribe steroids. Research shows that for many people, taking steroids by mouth can work just as…
Tweet Trial in secondary progressive MS has now been reported and it failed to show a positive effect. We will have to wait for the imaging elements to surface Chataway J, Williams T, Blackstone J, John N, Braisher M, De Angelis F, Bianchi A, Calvi…